您的位置：
首页
>
农业专利
>
详情页
Use of nicotinic acetylcholine receptor alpha 7 activators
专利权人:
Novartis AG
发明人:
Feuerbach, Dominik,Gomez-Mancilla, Baltazar,Lopez-Lopez, Cristina,Johns, Donald,Di Paolo, Therese
申请号：
AU2012210652
公开号：
AU2012210652B2
申请日:
2012.01.20
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of a Movement Disorder selected from Dystonia, Dyskinesia, Chorea, Restless Legs Syndrome, Tics, Tremor, Myoclonus, Startle, Stiff Person Syndrome, Gait Disorder, Parkinson's Disease and Symptomatic Parkinsonism.
来源网站：
中国工程科技知识中心
来源网址：
http://www.ckcest.cn/home/
相关专利
USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
Use of nicotinic acetylcholine receptor α7 activator
ПРИМЕНЕНИЕ АКТИВАТОРОВ НИКОТИНОВЫХ АЦЕТИЛХОЛИНОВЫХ РЕЦЕПТОРОВ АЛЬФА-7
COMPOUND； COMPOSITION； METHOD OF TREATMENT AND / OR PREVENTION OF MIGRAINE, ALS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, EXTRAPYRIMIDAL DISORDERS, DEPRESSION, NAUSEA, AEMESIS, SYNDROME OF THE WASTE LEGS, INSOMENESS, HYGERNESS, AGING , ANXIETY, DRUG DEPENDENCIES, DYSTONIA, PARASSONIA OR HYPERLACTINEMIA IN AN INDIVIDUAL； AGONIZATION METHODS OF D2, 5-HT1D, 5-HT1A AND 5-HT2C RECEPTORS, IN AN INDIVIDUAL； ANTAGONIZATION METHOD OF THE D3 RECEPTOR IN AN INDIVIDUAL； METHODS OF SELECTIVE AGONIZATION OF RECEPTORS 5 -HT1D, AND 5-HT2C, METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN RECEPTOR 5 -HT2
